Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation

The epigenetic silencing of tumor suppressor genes in myelodysplastic syndromes (MDS) can potentially confer a growth advantage to individual cellular clones. Currently, the recommended treatment for patients with high-risk MDS is the methylation agent decitabine (DAC), a drug that can induce the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Wen, Dai, Hanjun, Yan, Ming, Cai, Xiaojun, Luo, Hong, Ke, Min, Liu, Zeming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662805/
https://www.ncbi.nlm.nih.gov/pubmed/29124072
http://dx.doi.org/10.1155/2017/4302320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662805/
https://www.ncbi.nlm.nih.gov/pubmed/29124072
http://dx.doi.org/10.1155/2017/4302320

Ejemplares similares